Inclusion Criteria:

        General:

        ECOG performance status ≤1

        • Disease Related:

          -  Have a histologically or cytologically confirmed diagnosis of r/r B cell NHL or CLL or
             B-ALL as defined by WHO 2016 classification

          -  Subjects who received prior CD19-directed therapy must have disease that remains CD19+

          -  Have measurable disease

          -  Have received ≥2 lines of therapy except subjects with MCL and WM, who must have
             received at least 1 prior line of therapy

          -  Have received a combination of an anti CD20 monoclonal antibody and cytotoxic
             chemotherapy for subjects with NHL

          -  Received:

               -  BTKi for subjects with MCL, CLL/SLL, WM, and other indications where a BTKi is
                  approved

               -  Venetoclax for subjects with CLL/SLL

               -  Tyrosine kinase inhibitor for subjects with Philadelphia chromosome (Ph+) B-ALL

          -  Not responded or relapsed within 12 months of completion of their prior line of
             therapy, with the exception of a newly diagnosed Richter's transformation of CLL/SLL
             or other transformation of an indolent lymphoma, including from WM

          -  Adequate organ function

          -  White blood cell count of ≤20 × 109/L

          -  Platelet count ≥30,000/uL

        Exclusion Criteria:

        • Disease related:

          -  Burkitt Lymphoma, primary CNS lymphoma, Richter's transformation to Hodgkin lymphoma

          -  Subjects with WM who underwent plasmapheresis <35 days prior to the first dose of
             NKX019

          -  Subjects with NHL with any evidence of active CNS malignancy

          -  Subjects with B-ALL who have extramedullary disease (EMD)

          -  Subjects with any prior cellular therapy except subjects enrolling in selected LBCL
             expansion cohort who must have received prior CD19 directed CAR T therapy, recent HCT,
             or complications from HCT

          -  Recent use of any cancer-directed therapy within protocol specified window prior to
             the first dose of NKX019

          -  Residual toxicities ≥Grade 2 due to prior therapy

          -  Other comorbid conditions and concomitant medications prohibited as per study protocol

          -  Pregnant or lactating female